Dake Benjamin T's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Sep 12, 2022
- Accession no.
- 0001493152-22-025660
- Filed
- Sep 12, 2022
- Trade date
- Sep 8-9, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 4 derivative transactions. Open-market sales total $139.6K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dake Benjamin TCIK 0001869248 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2022 | Common Stock | MOption exerciseAcquired | +3,120 | $1.74 | +$5,428.8 | 3,120 | Direct | |
| Sep 8, 2022 | Common Stock | SSaleDisposed | −2,491 | $18.14F2 | −$45,186.74 | 629 | Direct | |
| Sep 8, 2022 | Common Stock | SSaleDisposed | −629 | $18.42F3 | −$11,586.18 | 0 | Direct | |
| Sep 9, 2022 | Common Stock | MOption exerciseAcquired | +258 | $1.74 | +$448.92 | 258 | Direct | |
| Sep 9, 2022 | Common Stock | MOption exerciseAcquired | +4,462 | $2.14 | +$9,548.68 | 4,720 | Direct | |
| Sep 9, 2022 | Common Stock | SSaleDisposed | −4,544 | $17.50F4 | −$79,520 | 176 | Direct | |
| Sep 9, 2022 | Common Stock | SSaleDisposed | −176 | $18.54F5 | −$3,263.04 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2022 | Common Stock | MOption exerciseDisposed | −648 | $0.00 | $0 | 14,746 | Direct | |
| Sep 8, 2022 | Common Stock | MOption exerciseDisposed | −2,472 | $0.00 | $0 | 34,656 | Direct | |
| Sep 9, 2022 | Common Stock | MOption exerciseDisposed | −258 | $0.00 | $0 | 14,488 | Direct | |
| Sep 9, 2022 | Common Stock | MOption exerciseDisposed | −4,462 | $0.00 | $0 | 44,420 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.39 to $18.385, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.40 to $18.505, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.06 to $18.06, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.07 to $18.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer Title: President, Chief Operating Officer and Secretary